Citations

Mayo Clinic

Showing 10 of 108572 citations.

Association between structural brain MRI abnormalities and epilepsy in older adults
Gugger, James J. , Walter, Alexa E. , Huang, Juebin , Jack, Clifford R. , Reid, Robert I. , Kucharska‐Newton, Anna , Schneider, Andrea L.C. , Johnson, Emily L. , Reid, Robert I , Gottesman, Rebecca F , Schneider, Andrea L C , Johnson, Emily L , Jack, Clifford R , Kucharska-Newton, Anna M , Diaz‐Arrastia, Ramon , Gottesman, Rebecca F.

Annals of Clinical and Translational Neurology | December 29, 2023 | Volume: 11 | Issue: 2 | Pages: 342-354

10.1002/acn3.51955 | PMID 38155477 Get It

Abstract Objective To determine the association between brain MRI abnormalities and incident epilepsy in older adults. Methods Men and women (ages 45–64 years) from the Atherosclerosis Risk in Communities study were followed up from 1987 to 2018 with brain MRI performed between 2011 and 2013. We identified cases of incident late‐onset epilepsy (LOE) with onset of seizures occurring after the acquisition of brain MRI. We evaluated the relative pattern of cortical thickness, subcortical volume, and white matter integrity among participants with incident LOE after MRI in comparison with participants without seizures. We examined the association between MRI abnormalities and incident LOE using Cox proportional hazards regression. Models were adjusted for demographics, hypertension, diabetes, smoking, stroke, and dementia status. Results Among 1251 participants with brain MRI data, 27 (2.2%) developed LOE after MRI over a median of 6.4 years (25–75 percentile 5.8–6.9) of follow‐up. Participants with incident LOE after MRI had higher levels of cortical thinning and white matter microstructural abnormalities before seizure onset compared to those without seizures. In longitudinal analyses, greater number of abnormalities was associated with incident LOE after controlling for demographic factors, risk factors for cardiovascular disease, stroke, and dementia (gray matter: hazard ratio [HR]: 2.3, 95% confidence interval [CI]: 1.0–4.9; white matter diffusivity: HR: 3.0, 95% CI: 1.2–7.3). Interpretation This study demonstrates considerable gray and white matter pathology among individuals with LOE, which is present prior to the onset of seizures and provides important insights into the role of neurodegeneration, both of gray and white matter, and the risk of LOE.
Breast Cancer Polygenic-Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-Up
Stan, Daniela , Kim, Julian O. , Schaid, Daniel J. , Carlson, Erin E. , Kim, Christina , Couch, Fergus J. , Vachon, Celine M. , Cooke, Andrew , Goldenberg, Benjamin A. , Pruthi, Sandhya , Couch, Fergus J. , Stan, Daniela L , Kim, Christina A , Sinnwell, Jason P , Vachon, Celine M. , Cooke, Andrew L , Goldenberg, Benjamin , Pruthi, Sandhya , Sinnwell, Jason P.

Cancer Prevention Research | December 28, 2023 | Volume: 17 | Issue: 2 | Pages: 77-84

10.1158/1940-6207.capr-23-0256 | PMID 38154464 Get It

Abstract Refinement of breast cancer risk estimates with a polygenic-risk score (PRS) may improve uptake of risk-reducing endocrine therapy (ET). A previous clinical trial assessed the influence of adding a PRS to traditional risk estimates on ET use. We stratified participants according to PRS-refined breast cancer risk and evaluated ET use and ET-related quality of life (QOL) at 1-year (previously reported) and 2-year follow-ups. Of 151 participants, 58 (38.4%) initiated ET, and 22 (14.6%) discontinued ET by 2 years; 42 (27.8%) and 36 (23.8%) participants were using ET at 1- and 2-year follow-ups, respectively. At the 2-year follow-up, 39% of participants with a lifetime breast cancer risk of 40.1% to 100.0%, 18% with a 20.1% to 40.0% risk, and 16% with a 0.0% to 20.0% risk were taking ET (overall P = 0.01). Moreover, 40% of participants whose breast cancer risk increased by 10% or greater with addition of the PRS to a traditional breast cancer-risk model were taking ET versus 0% whose risk decreased by 10% or greater (P = 0.004). QOL was similar for participants taking or not taking ET at 1- and 2-year follow-ups, although most who discontinued ET did so because of adverse effects. However, these QOL results may have been skewed by the long interval between QOL surveys and lack of baseline QOL data. PRS-informed breast cancer prevention counseling has a lasting, but waning, effect over time. Additional follow-up studies are needed to address the effect of PRS on ET adherence, ET-related QOL, supplemental breast cancer screening, and other risk-reducing behaviors. Prevention Relevance: Risk-reducing medications for breast cancer are considerably underused. Informing women at risk with precise and individualized risk assessment tools may substantially affect the incidence of breast cancer. In our study, a risk assessment tool (IBIS-polygenic-risk score) yielded promising results, with 39% of women at highest risk starting preventive medication.
Adenomyoepithelioma of the Breast: Radiologic-Pathologic Correlation and Management
Smith, Katherine , Solanki, Malvika , Glazebrook, Katrina N. , Smith, Katherine A , Solanki, Malvika H

Journal of Breast Imaging | December 28, 2023 | Volume: 6 | Issue: 1 | Pages: 64-71

10.1093/jbi/wbad098 | PMID 38153758 Get It

Abstract Adenomyoepithelioma (AME) is a rare, usually benign breast neoplasm with low potential for malignant transformation. Imaging features are nonspecific and overlap with other benign and malignant breast lesions. On mammography, AME most often presents as a mass, usually oval in shape, with variable reported margins. Less commonly, AME can present mammographically as an asymmetry or can be mammographically occult. Associated calcifications are uncommon. On US, AME is usually seen as a hypoechoic oval mass, but it can also manifest as a complex cystic and solid mass. On US, the majority of AME have noncircumscribed margins (indistinct, angular, or microlobulated). Internal vascularity is usually present, and posterior enhancement can be seen. Although there is limited literature on MRI features, the most frequent finding is an irregular mass with washout kinetics; T2 hyperintensity can be observed. These nonspecific and often suspicious imaging features usually merit biopsy. On histologic analysis, AME is characterized by a biphasic proliferation of myoepithelial and epithelial cells. Pathologic diagnosis can be difficult due to the variety of histologic features of AME and heterogeneity in these tumors, especially when sampling is limited, such as in core needle biopsies. Wide local surgical excision of AME is recommended due to potential for recurrence and malignant transformation.
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
Kyalwazi, Beverly , Campbell, Michael J. , Chien, A. Jo , Forero-Torres, Andres , Ellis, Erin D. , Albain, Kathy S. , Haley, Barbara , Clark, Amy S. , Nanda, Rita , Yung, Rachel L. , Tripathy, Debasish , Edmiston, Kristen K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Asare, Smita , Wilson, Amy , Hirst, Gillian L. , Lu, Ruixiao , Symmans, W. Fraser , Yee, Douglas , Veer, Laura van ‘t , Esserman, Laura J. , Olopade, Olufunmilayo I. , Tripathy, Debu , Olopade, Olufunmilayo I , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , Yau, Christina , Yoshimatsu, Toshio F. , Wallace, Anne M. , Pusztai, Lajos , Blaes, Anne , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Han, Hyo S , DeMichele, Angela , Veer, Laura J. van’t

JAMA Network Open | December 28, 2023 | Volume: 6 | Issue: 12 | Pages: e2349646

10.1001/jamanetworkopen.2023.49646 | PMID 38153734 Get It

ImportanceThere has been little consideration of genomic risk of recurrence by breast cancer subtype despite evidence of racial disparities in breast cancer outcomes.ObjectiveTo evaluate associations between clinical trial end points, namely pathologic complete response (pCR) and distant recurrence–free survival (DRFS), and race and examine whether gene expression signatures are associated with outcomes by race.Design, Setting, and ParticipantsThis retrospective cohort study used data from the Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2 (I-SPY 2) multicenter clinical trial of neoadjuvant chemotherapy with novel agents and combinations for patients with previously untreated stage II/III breast cancer. Analyses were conducted of associations between race and short- and long-term outcomes, overall and by receptor subtypes, and their association with 28 expression biomarkers. The trial enrolled 990 female patients between March 30, 2010, and November 5, 2016, with a primary tumor size of 2.5 cm or greater and clinical or molecular high risk based on MammaPrint or hormone receptor (HR)-negative/ERBB2 (formerly HER2 or HER2/neu)–positive subtyping across 9 arms. This data analysis was performed between June 10, 2021, and October 20, 2022.ExposureRace, tumor receptor subtypes, and genomic biomarker expression of early breast cancer.Main Outcomes and MeasuresThe primary outcomes were pCR and DRFS assessed by race, overall, and by tumor subtype using logistic regression and Cox proportional hazards regression models. The interaction between 28 expression biomarkers and race, considering pCR and DRFS overall and within subtypes, was also evaluated.ResultsThe analytic sample included 974 participants (excluding 16 self-reporting as American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or multiple races due to small sample sizes), including 68 Asian (7%), 120 Black (12%), and 786 White (81%) patients. Median (range) age at diagnosis was 47 (25-71) years for Asian, 49 (25-77) for Black, and 49 (23-73) years for White patients. The pCR rates were 32% (n = 22) for Asian, 30% for Black (n = 36), and 32% for White (n = 255) patients (P = .87). Black patients with HR-positive/ERBB2-negative tumors not achieving pCR had significantly worse DRFS than their White counterparts (hazard ratio, 2.28; 95% CI, 1.24-4.21; P = .01), with 5-year DRFS rates of 55% (n = 32) and 77% (n = 247), respectively. Black patients with HR-positive/ERBB2-negative tumors, compared with White patients, had higher expression of an interferon signature (mean [SD], 0.39 [0.87] and −0.10 [0.99]; P = .007) and, compared with Asian patients, had a higher mitotic score (mean [SD], 0.07 [1.08] and −0.69 [1.06]; P = .01) and lower estrogen receptor/progesterone receptor signature (mean [SD], 0.31 [0.90] and 1.08 [0.95]; P = .008). A transforming growth factor β signature had a significant association with race relative to pCR and DRFS, with a higher signature associated with lower pCR and worse DRFS outcomes among Black patients only.Conclusions and RelevanceThe findings show that women with early high-risk breast cancer who achieve pCR have similarly good outcomes regardless of race, but Black women with HR-positive/ERBB2-negative tumors without pCR may have worse DRFS than White women, highlighting the need to develop and test novel biomarker-informed therapies in diverse populations.
Advancements in Bioengineered Corneas for Vision Restoration -A Systematic Review
Ye, En Hui , Ye, En Zhou , Ye, Joseph , Ye, Joseph, Ye, Run Zhou

No container title available | December 28, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.170379744.41776804/v1 Get It

Clinical remission following plasmapheresis and corticosteroid treatment in a dog with acquired myasthenia gravis
Bartges, Joseph W. , Klausner, Jeffrey S., Bostwick, Eileen F., Hakala, Joyce E., Lennon, Vanda A.

Journal of the American Veterinary Medical Association | December 28, 2023 | Volume: 196 | Issue: 8 | Pages: 1276-1278

10.2460/javma.1990.196.08.1276 Get It

Surgical correction of an acquired vaginal stricture in a llama, using a carbon-dioxide laser
Bennett, James G., Kennel, Arthur J., Stanhope, C.Robert

Journal of the American Veterinary Medical Association | December 28, 2023 | Volume: 212 | Issue: 9 | Pages: 1436-1437

10.2460/javma.1998.212.09.1436 Get It

Dense Lichenoid Inflammation in Paget Disease: A Diagnostic Pitfall
Zayas, Jacqueline , Sokumbi, Olayemi

The American Journal of Dermatopathology | December 28, 2023 | Volume: 46 | Issue: 3 | Pages: 175-178

10.1097/dad.0000000000002611 | PMID 38153267 Get It

Abstract: Mammary Paget disease is a rare form of breast cancer, which typically presents as an eczematous plaque on the nipple or surrounding skin. It is often a clinical diagnosis that is confirmed with skin biopsy. Histologic hallmarks of mammary Paget disease include large, pleomorphic, malignant, ductal epithelial cells within the epidermis. Chronic lichenoid inflammation may be seen in the papillary dermis but is not diagnostic. Because mammary Paget disease often overlies ductal carcinoma in situ or invasive carcinoma of the breast, prompt bilateral mammography is warranted. We report a case of Paget disease of the nipple with negative breast imaging that was originally misdiagnosed due to a dense lichenoid infiltrate obscuring the neoplasm.
Utility of the Japanese version of the Clinical Dementia Rating® plus National Alzheimer's Coordinating Centre Behaviour and Language Domains for sporadic cases of frontotemporal dementia in Japan
Taomoto, Daiki , Sato, Shunsuke , Kanemoto, Hideki , Suzuki, Maki , Hirakawa, Natsuho, Takasaki, Akihiro , Akimoto, Miu, Satake, Yuto , Koizumi, Fuyuki , Yoshiyama, Kenji , Takahashi, Rei , Shigenobu, Kazue, Hashimoto, Mamoru , Miyagawa, Toji , Mori, Etsuro , Ikeda, Manabu , Boeve, Bradley F. , Knopman, David S.

Psychogeriatrics | December 28, 2023 | Volume: 24 | Issue: 2 | Pages: 281-294

10.1111/psyg.13072 | PMID 38152057 Get It

AbstractBackgroundWe aimed to validate the Clinical Dementia Rating (CDR®) dementia staging instrument plus the National Alzheimer's Coordinating Centre Behaviour and Language Domains (CDR® plus NACC FTLD) for use in clinical settings in Japan and in the Japanese language.MethodsThis prospective observational study enrolled 29 patients with frontotemporal dementia (FTD) and 21 patients with Alzheimer's disease (AD) dementia from the Departments of Psychiatry at Osaka University Hospital and Asakayama General Hospital and the Brain Function Centre at Nippon Life Hospital. CDR® plus NACC FTLD, CDR®, Mini‐Mental State Examination (MMSE), Western Aphasia Battery (WAB), Neuropsychiatric Inventory‐plus (NPI‐plus), Stereotypy Rating Inventory (SRI), and frontal behavioural symptom scores obtained from items of NPI‐plus and SRI, were conducted to assess inter‐ and intra‐rater reliability, validity, and responsiveness. We performed receiver operating characteristic (ROC) curve analysis to evaluate the discriminating power of the Behaviour/Comportment/Personality (BEHAV) and Language (LANG) domains of the CDR® plus NACC FTLD and the MEMORY domain of the CDR® in patients AD dementia and FTD.ResultsThe CDR® plus NACC FTLD showed good inter‐ and intra‐rater reliabilities. In patients with FTD, the BEHAV domain of the CDR® plus NACC FTLD was significantly correlated with all clinical measures except for the SRI total score, while the LANG domain of the CDR® plus NACC FTLD was significantly correlated with the MMSE and the WAB‐Aphasia quotient. In addition, the CDR® plus NACC FTLD sum of boxes significantly changed after 6 months and after 1 year. ROC curve analysis showed that the BEHAV and LANG domains of the CDR® plus NACC FTLD distinguished between patients with AD dementia and FTD better than the MEMORY domain of the CDR®.ConclusionsThis study validated the Japanese version of the CDR® plus NACC FTLD with good reliability, validity, and responsiveness.
Prescription Microbiome Therapeutic for Recurrent Clostridioides difficile Infection: Fecal Microbiota Live-jslm
Oneto, Caterina , Khanna, Sahil

American Journal of Gastroenterology | December 28, 2023 | Volume: 119 | Issue: 1S | Pages: S16-S21

10.14309/ajg.0000000000002577 | PMID 38153221 Get It